Publication Details

Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.

Banka G, Heidenreich PA, Fonarow GC. J Am Coll Cardiol. 2013; 61 (13): 1440-6

This study sought to quantify the incremental cost-effectiveness ratios (ICER) of angiotensin-converting enzyme inhibitor (ACEI), beta-blocker (BB), and aldosterone antagonist (AldA) therapies for patients with heart failure with reduced ejection fraction (HFrEF).

PubMedID: 23433562